558 related articles for article (PubMed ID: 19032235)
1. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe.
Canonica GW; Poulsen PB; Vestenbaek U
Respir Med; 2007 Sep; 101(9):1885-94. PubMed ID: 17611095
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.
Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB
Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225
[TBL] [Abstract][Full Text] [Related]
4. [Economic evaluation of a tablet-based vaccination against hay fever in Denmark].
Poulsen PB; Pedersen KM; Christensen J; Vestenbaek U
Ugeskr Laeger; 2008 Jan; 170(3):138-42. PubMed ID: 18208729
[TBL] [Abstract][Full Text] [Related]
5. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.
Westerhout KY; Verheggen BG; Schreder CH; Augustin M
J Med Econ; 2012; 15(5):906-17. PubMed ID: 22533527
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.
Brüggenjürgen B; Reinhold T; Brehler R; Laake E; Wiese G; Machate U; Willich SN
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):316-24. PubMed ID: 18814456
[TBL] [Abstract][Full Text] [Related]
10. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
11. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
12. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
13. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France.
Omnes LF; Bousquet J; Scheinmann P; Neukirch F; Jasso-Mosqueda G; Chicoye A; Champion L; Fadel R
Eur Ann Allergy Clin Immunol; 2007 May; 39(5):148-56. PubMed ID: 17626329
[TBL] [Abstract][Full Text] [Related]
15. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
16. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.
Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR
J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284
[TBL] [Abstract][Full Text] [Related]
17. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
18. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis.
Valovirta E; Berstad AK; de Blic J; Bufe A; Eng P; Halken S; Ojeda P; Roberts G; Tommerup L; Varga EM; Winnergard I;
Clin Ther; 2011 Oct; 33(10):1537-46. PubMed ID: 21999887
[TBL] [Abstract][Full Text] [Related]
19. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
Nelson H; Lehmann L; Blaiss MS
Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
